Psilocybin-Research.com Research. Clarity. Progress.
Loading
Psilocybin-Research.com Research. Clarity. Progress.

Psilocybin Research Publication Tracker

Search, analyze, export, and monitor psilocybin and psilocin literature across peer-reviewed papers, preprints, reviews, protocols, and clinical trials.

Database up to date Last update: Jul 3, 2026 01:22 UTC
Database 3,975 indexed records 3,975 Total Publications 3,834 Psilocybin Records 553 Psilocin Records 3,975 Search Matches 388 Journals 66 Research Topics
Published 3,210 Peer-reviewed / formal records
Preprints 478 Marked as not peer reviewed
Clinical trials 287 ClinicalTrials.gov records
Source coverage 8 active sources
Source Count Share Status
Europe PMC 2,554 64.3% Active
PubMed 302 7.6% Active
ClinicalTrials.gov 287 7.2% Active
OpenAlex 283 7.1% Active
PsyArXiv 216 5.4% Active
Crossref 157 3.9% Active
bioRxiv 142 3.6% Active
Publication timeline 3,072 dated records
3,072 records since 2020
Annual records Cumulative line
Current display Latest publications Full SQLite index sorted by newest first. Use search or filters to narrow the list.
Default publication index

Latest publications

3,975 records from the full SQLite publication database, sorted by newest first.

Page 21 of 199
Updated Jul 3, 2026 01:22 UTC
Checking for newly published papers…

Psilocybin Treatment as an Adjunct to Cognitive Behavioral Therapy for Eating Disorders: Therapeutic Rationale & Considerations for Protocol Development.

Eating disorders (EDs) remain challenging to treat, with high dropout and low remission rates in cognitive-behavioral therapy for EDs (CBT-ED). Psilocybin treatment (PT) demonstrates therapeutic potential to enhance CBT-ED by exerting several neurobiological, psychological, and experiential effects (e.g., antidepressant, neuroplasticity, emotional openness) ...

Unknown journal 2026-03-05 Koning E, Gamberg S, Keshen A.
Europe PMC Published psilocybin Eating DisordersNeuroplasticityEmotional ProcessingReview ArticleSafety Review Article

Pilot Proof of Concept Study Evaluating the Potential Psilocybin Assisted Psychotherapy (PAP) as a Therapeutic Tool for Patients Suffering From Severe Irritable Bowel Syndrome.

This study will serve as a pilot randomized controlled trial to assess the feasibility of Psilocybin-Assisted Psychotherapy (PAP) in Treating Irritable Bowel Syndrome (IBS). Patients with severe IBS will undergo 3 pre-psychotherapy sessions with two licensed and trained psychedelic therapists, then will be randomized to undergo a guided psychotherapy session...

ClinicalTrials.gov 2026-03-04 NYU Langone Health
ClinicalTrials.gov CLINICAL TRIAL psilocybin Randomized Controlled Trial Randomized Controlled Trial IBS - Irritable Bowel SyndromePsilocybin 25 mg

Efficacy and risks of psychedelics in treatment of posttraumatic stress disorder: A systematic review.

PurposeThe purpose of this review is to evaluate which psychedelics have the most efficacy data to support their use in the treatment of posttraumatic stress disorder (PTSD). This review also aims to assess safety data and concerns related to psychedelic therapies and identify demographic characteristics that may influence clinical outcomes.SummaryA systemat...

Unknown journal 2026-03-04 Thomas JE, Dellarole A, Caballero J.
Europe PMC Published psilocybin PTSDRandomized Controlled TrialSystematic ReviewReview ArticleVeteransSafety Randomized Controlled Trial

Examining the Safety and Clinical Efficacy of Psilocybin Therapy for Veterans With PTSD: An Open-Label Proof-of-Concept Trial

The primary aim of this study is to assess the safety and efficacy of psilocybin-assisted therapy in the treatment of post-traumatic stress disorder in United States military Veterans. The objective of this study is to determine the safety and efficacy of psilocybin assisted psychotherapy in the treatment of Veterans with PTSD. This study will recruit 15 Uni...

ClinicalTrials.gov 2026-03-03 Ohio State University
ClinicalTrials.gov CLINICAL TRIAL psilocybin PTSDVeteransSafety Other PTSDStress Disorders

Inhibition of cortico-amygdala projections underlies affective bias modification by psilocybin

Psilocybin, a serotonergic psychedelic, can produce rapid and enduring antidepressant effects in patients with major depressive disorder (MDD)[1, 2], yet the neural mechanisms underlying these effects remain unclear. Negative affective biases are an important neuropsychological mechanism central to the development and perpetuation of MDD[3]. Using a translat...

bioRxiv 2026-03-03 Claydon MDB, Hinchcliffe JK, Bartlett J, Golden CT, Thomas CW, Gilmour G, Mellor JR, Bortolotto ZA, Robinson ESJ.
bioRxiv PREPRINT (not peer reviewed) psilocybinpsilocin DepressionNeuroplasticityMechanism of ActionReceptor PharmacologyAnimal Study Animal Study

Serotonergic modulation of cortical gamma synchronization: right-lateralized psilocin effects on 40 Hz auditory steady-state responses in rats.

Auditory steady-state responses (ASSRs), particularly at 40 Hz, are promising biomarkers for psychiatric disorders involving dysregulated neural synchronization. Although most ASSR studies have focused on the glutamatergic system, the serotonergic system, specifically 5-HT2A receptor signaling, has received limited attention. Psilocin, the active metabolite ...

Unknown journal 2026-03-03 Griškova-Bulanova I, Vejmola Č, Páleníček T.
Europe PMC Published psilocybinpsilocin Brain ImagingMechanism of ActionReceptor PharmacologyBiomarkersAnimal Study Animal Study AnimalsRats

A Phase 2b Double-blind, Randomized, Low-dose Comparator-controlled Clinical Trial to Assess the Efficacy and Safety of NPX-5 in Psilocybin-assisted Psychotherapy for the Treatment of Adjustment Disorder Associated With Cancer.

This study is assessing the efficacy and safety of NPX-5 in psilocybin-assisted psychotherapy for the treatment of adjustment disorder due to cancer diagnosis. Who is it for? This study is for people who are aged between 18 and 80 years old and suffer from anxiety after adjusting to an acutely stressful event of their cancer diagnosis. This is called adjustm...

ClinicalTrials.gov 2026-03-02 Psyence Australia Pty Ltd
ClinicalTrials.gov CLINICAL TRIAL psilocybin DepressionAnxietyClinical TrialSafety Clinical Trial Adjustment DisorderAdjustment Disorder With Anxious Mood

Study of Psilocybin for Anorexia in Young Adults

This is a single site trial of psilocybin therapy for the treatment of refractory Anorexia Nervosa in young adults. The psilocybin therapy will include three preparatory sessions, psilocybin dosing session one (20mg), two integration sessions, psilocybin dosing session two (up to 25mg), and three final integration sessions. Eating disorder symptoms will be m...

ClinicalTrials.gov 2026-03-02 Marissa Raymond-Flesch, MD, MPH
ClinicalTrials.gov CLINICAL TRIAL psilocybin Eating Disorders Other Anorexia NervosaPsilocybin

Differential Effects of Acute and Chronic Fluoxetine on Psychedelic-Induced Behavior in Mice: Implications for Clinical Trials.

Selective serotonin reuptake inhibitors (SSRIs) are widely prescribed for mood and anxiety disorders, the same conditions under which psychedelic-assisted therapies are gaining renewed interest. However, it remains unclear how SSRI treatment may influence sensitivity to psychedelics, particularly through the shared engagement of serotonergic pathways. Here, ...

Unknown journal 2026-03-02 Wood BJ, Vest MF, Carfagno C, Bartley KR, Sharma P, Halberstadt AL, Blough BE, Murnane KS.
Europe PMC Published psilocybin AnxietyMechanism of ActionReceptor PharmacologyClinical TrialAnimal StudyDrug Interactions Clinical Trial

Synthesis and Characterization of Psilocybin Metabolites and Deuterated Analogs.

To support ongoing clinical trials, the major human metabolites of psilocybin were synthesized on a preparative scale, specifically psilocin-O-glucuronide and 4-hydroxyindole-3-acetic acid (4-HIAA), along with putative minor metabolites and several deuterium-labeled derivatives. Psilocybin, psilocin, psilocin-O-glucuronide, and 4-HIAA were assayed for engage...

Unknown journal 2026-03-02 Williamson SE, Burkhartzmeyer EK, Faley MT, Ohana RF, Guzei IA, Valley M, Cali JJ, Sherwood AM.
Europe PMC Published psilocybinpsilocin Receptor PharmacologyClinical Trial Clinical Trial HumansDeuterium

Multidimensional Ego-Dissolution Assessment (MEDA): Scale Development and Substance-Specific Comparisons

Rationale: Ego-dissolution represents a key therapeutic mechanism in psychedelic-assisted therapy, yet current measurement approaches may inadequately capture its multidimensional nature. Objective: To develop and validate the Multidimensional Ego-Dissolution Assessment (MEDA) and examine substance-specific patterns across classical psychedelics. Methods: It...

PsyArXiv 2026-03-01 Senānāyaka R.
PsyArXiv PREPRINT (not peer reviewed) psilocybin ConsciousnessMystical Experience Other

Effects of Psilocybin on Electrophysiology and the Dynamic Content of Thought

This research study will use computerized tasks, electroencephalography (EEG), and magnetic resonance imaging (MRI) to look at how the drug psilocybin, a naturally occurring compound contained in hundreds of species of psychoactive mushrooms, changes thoughts and brain activity. In this double-blind, placebo-controlled, within-subject, full cross-over study ...

ClinicalTrials.gov 2026-03-01 Johns Hopkins University
ClinicalTrials.gov CLINICAL TRIAL psilocybin Brain ImagingConsciousnessAgingCreativityHealthy Volunteers Other HealthyPsilocybin

Multidimensional Ego-Dissolution Assessment (MEDA): Scale Development and Substance-Specific Comparisons

Rationale: Ego-dissolution represents a key therapeutic mechanism in psychedelic-assisted therapy, yet current measurement approaches may inadequately capture its multidimensional nature. Objective: To develop and validate the Multidimensional Ego-Dissolution Assessment (MEDA) and examine substance-specific patterns across classical psychedelics. Methods: It...

PsyArXiv 2026-03-01 Authors unavailable
PsyArXiv PREPRINT (not peer reviewed) psilocybin ConsciousnessMystical Experience Other ego-dissolutionfactor analysis

Psilocybin or Nicotine Patch for Smoking Cessation: A Pilot Randomized Clinical Trial.

ImportanceAnnual tobacco-related death estimates are 480 000 in the US and 8 million worldwide, surpassing mortality for other abused substances. Most smoking cessation interventions result in modest long-term success.ObjectiveTo compare prolonged smoking abstinence rates in smokers receiving psilocybin plus cognitive behavioral therapy (CBT) with those rece...

Unknown journal 2026-03-01 Johnson MW, Naudé GP, Hendricks PS, Garcia-Romeu A.
Europe PMC Published psilocybin AddictionClinical TrialAdverse Events Clinical Trial HumansTreatment Outcome

Journeying into Right Relations: Scientists Turn to Psilocybin to Shift Psychological Burdens of Global Environmental Change and Find Transformational Pathways Forward

This paper follows 8 scientists who ventured into the world of psychedelics on a quest to find transformational pathways forward. Each have worked on aspects of global environmental change for decades, and observing environmental crises converging into a global polycrisis/metacrisis with genuine potential for collapse, we have all carried psychological burde...

Action Research 2026-02-28 Wrathall David J., Gosnell Hannah, Wickson Fern, Spanger Erika, Associates*
Crossref Published psilocybin AnxietyMechanism of ActionResilienceCreativity Other

Meaning and Psychedelics in Palliative Care: A Narrative Review.

Meaning is a primary existential concern in those with advanced illnesses and functions as an important coping mechanism. Loss of meaning contributes to existential distress, and, in particular, may manifest as demoralization, a syndrome of poor coping that is associated with negative outcomes. Psychedelics are unique psychoactive compounds that, among other...

Journal of pain and symptom management 2026-02-28 Alexander WB, Hansen ED, Anderson BT, Zarrabi AJ, Rogers AH, Loewen G, Ficarro ZR, Alexander MH, Schaefer D, Case AA
PubMed Published psilocybin End-of-Life DistressClinical TrialReview ArticleSafety Clinical Trial DemoralizationLSD

Psilocybin and Ibogaine in Cocaine-Seeking: Extinction Enhancement Without Relapse Prevention.

Psychedelics have emerged as potential therapeutics for substance use disorders, yet preclinical data validating their efficacy remain limited. Here, we investigated the effects of a clinically inspired dose-escalation protocol of psilocybin and ibogaine on extinction and cue-induced reinstatement in Wistar male rats following intravenous cocaine self-admini...

Unknown journal 2026-02-28 Koutrouli IRA, Brejtr V, Schwendt M, Witek K, Charalambous C, Aleksič K, Miniariková N, Lhotková E, Toman M, Nikolič M, Jurok R, Cihlářová P, Mazoch V, Ryšánek P, Kuchař M, Šíchová K, Páleníček T.
Europe PMC Published psilocybin AnxietyAddictionAnimal StudyAdverse Events Clinical Trial AnimalsRats

Live source coverage

3,975 indexed records across 8 active sources.

3,210Published
478Preprints
287Clinical trials
  1. Europe PMC 2,554 records · 64.3%
  2. PubMed 302 records · 7.6%
  3. ClinicalTrials.gov 287 records · 7.2%
  4. OpenAlex 283 records · 7.1%
  5. PsyArXiv 216 records · 5.4%
  6. Crossref 157 records · 3.9%
  7. bioRxiv 142 records · 3.6%
  8. medRxiv 34 records · 0.9%

Counts exclude hidden records and curated false positives. Preprints remain labeled as not peer reviewed in search results and exports.